Marco Meglio

At 180 days after surgery, weighted disability scores were better with surgery plus medical management than with medical management alone.

The smartphone tests accurately differentiated individuals with dementia from controls and were more sensitive to early symptoms than the Montreal Cognitive Assessment, a commonly used cognitive screening tool.

The new double-blind, placebo-controlled study includes approximately 200 patients with ALS who will undergo a single bone marrow aspiration procedure to procure the mesenchymal stem cells that will be used to manufacture each participant’s NurOwn treatment for the trial.

The new position statement proposes the use of CGRP-targeting therapies to be used as first-line treatments, eliminating the need to fail multiple medications before access.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.

Therapeutic effects were noticeable within 15–20 days post-injection, with five of six patients achieving complete pain relief.

Ganaxolone, a synthetic neurosteroid, has ongoing studies in tuberous sclerosis complex and super refractory status epilepticus, as well as upcoming research in Lennox-Gastaut syndrome and other epileptic encephalopathies.

SPN-830, an apomorphine infusion device, had its new drug application submitted using data from the phase 3 TOLEDO trial.

The presence of a sleep disorder was associated with a nearly 2-fold increase in the risk of increased health care utilization, with specific odds associated with individual sleep disorders.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on limb girdle muscular dystrophy.

The phase 1 study, dubbed PRO-101, assesses the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in both patients with ALS and healthy volunteers.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Francesco Saccà, MD, PhD. [LISTEN TIME: 18 minutes]

TUDCA, a hydrophilic bile acid that is normally produced endogenously in humans in the liver, failed to slow ALS disease progression in comaprison with placebo.

Ram Mukunda, chief executive officer of IGC Pharma, gave context to recently announced topline data highlighting IGC-AD1 as a potential option for Alzheimer disease agitation.

The associate professor of neurology at the University of Naples discussed a recently enrolled study assessing the use of dimethyl fumarate, an approved therapy for relapsing MS and psoriasis, in patients with Friedreich ataxia.

At some dose levels, the treatment appeared to slow the rate of motor function decline and regenerate sensory nerves in patients with giant axonal neuropathy.

Overall, the data empower the potential of CAR-T cell therapy for patients with advanced multiple sclerosis that are refractory to conventional antibody-mediated B cell depletion.

Advancements in the detection and care of multiple sclerosis have led to improved diagnosis rates and a more multidisciplinary approach to treating the autoimmune disorder.

The company also submitted a request for a fast track designation specific to a subcutaneous version of lecanemab and is expected to hear back within 60 days from March 2024.

Overall, the reduction of hyperactivity of delta- and gamma-band activities in mTBI suggest the treatment may reduce deafferentation and GABA-ergic inhibitory interneuron dysfunctions.

The APPRAISE randomized clinical trial provided clinically meaningful evidence that early initiation of migraine prevention with erenumab was superior over other nonspecific oral migraine preventive medications.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis and MS mimics.

The randomized, double-blind, placebo-controlled trial failed to show any beneficial symptomatic effect of 4-month treatment with 1.75–3.5 mg/day bumetanide on Parkinson disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Hesterlee, PhD. [LISTEN TIME: 10 minutes]

The findings were consistent with the chemical's known carcinogenicity and supportive of the emerging preclinical and epidemiological evidence that ties TCE exposure to patients with PD.

In a small-scale study, treatment with PRAX-628 resulted in significant reduction in the number of generalized photo paroxysmal response events.

Over the 24-week treatment period, satralizumab demonstrated a well tolerated safety profile that was consistent with its previous indication.

Following development and implementation of a simulation laboratory training session to all staff in the EMU, there were statistically significant improvements in orientation assessment, speech assessment, motor assessment, oxygen administration, and vital sign collection in the short-term reassessment.

With data showing significant therapeutic benefit on seizure reduction and other outcomes of cognition and behavior, Stoke will move forward with a new study to assess high doses of 70 mg STK-001 followed by continued dosing at 45 mg.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders and multiple system atrophy.